Search Results - beverly+mock

2 Results

Sort By:

Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy

Abstract: Available for licensing from the Laboratory of Cancer Biology and Genetics of the National Cancer Institute (NCI) is a novel gene signature of thirty-seven drug-responsive genes that links changes in gene expression to the clinically desirable outcome of improved overall survival. Expression of these genes has been linked to prognosis in several...

Published: 4/8/2024 | Inventor(s): Beverly Mock, John Simmons, Aleksandra Michalowski, Jyoti Patel

Keywords(s): Histone Deacetylase (HDAC), MELANOMA, mTOR, Myeloma, Rapamycin

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex

Abstract: The proto-oncogene c-Myc is deregulated and overexpressed in ~70% of all cancers. Thus, c-Myc is an attractive therapeutic target since disrupting c-Myc activity could be used as pan-chemotherapy. Beyond cancer, Myc is also a positive effector of tissue inflammation, and its function has been implicated in the pathophysiology of heart failure....

Published: 7/3/2024 | Inventor(s): John (Jay) Schneekloth, Kenneth Felsenstein, John Simmons, Lindsey Saunders, Beverly Mock, Peter Gareiss, David Calabrese, Elena Leon

Keywords(s): C-MYC, G-Quadruplex (G4), MULTIPLE MYELOMA, Schneekloth

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology